Quizartinib companion diagnostic - Daiichi Sankyo/GenoptixAlternative Names: AC220 companion diagnostic
Latest Information Update: 18 Nov 2014
At a glance
- Originator Genoptix
- Developer Daiichi Sankyo Company; Genoptix
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Acute myeloid leukaemia
Most Recent Events
- 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company